Scientific Research News

CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science Canada is excited to support the future of Canadian agriculture with its 2026 Bayer Crop Science Opportunity Scholarship. Through the scholarship, students entering post-secondary education in agriculture, food science or culinary arts are eligible for one of 12 scholarships valued at $5000 (CAD), with preference given to two applicants of Canadian Indigenous heritage. “The agriculture industry and our food system in Canada is evolving quick...

TOKYO--(BUSINESS WIRE)--Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device. Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the Nation...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort 8 of ENDEAVOR (Study 9001-103). The purpose of Cohort 8 is to assess prophylactic sirolimus treatment as part of an enhanced safety protocol during treatment with ELEVIDYS (delandistrogene moxeparvovec-rokl) in non-ambulant individuals with Duchenne muscular dystrophy. Data from Cohort 8 will be u...

FRAMINGHAM, Mass. & CHARLO, Mont.--(BUSINESS WIRE)--Ameresco, Inc., (NYSE: AMRC), a leading energy infrastructure solutions provider, today announced it has completed a comprehensive Energy Performance Contract (EPC) for Charlo School District in Charlo, Montana. Designed to create a more optimized learning environment, the project targeted modernizing aging infrastructure, improving indoor comfort, and reducing long-term energy and maintenance costs. Conducted in two phases, the project delive...

WALTHAM, Mass.--(BUSINESS WIRE)--Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Mark Vignola, Ph.D., has joined as Chief Financial Officer (CFO). Dr. Vignola brings extensive leadership experience in corporate finance across the biotech industry. “We are excited to welcome Mark as our Chief Financial Officer, with his extensive experience as a stra...

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a global leader in technology-enabled commercialization solutions for the life sciences industry, is sponsoring the Best Health Equity Innovation category at the 2026 Prix Galien UK Awards, one of the most prestigious global honors recognizing excellence in biopharmaceutical research and innovation. The awards ceremony will take place June 11, 2026, at the Natural History Museum in London, bringing together leading scientists, healthcare innovators, pol...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical data from the company’s cardio-pulmonary pipeline will be presented at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26) in New Orleans, La., from March 28-30. The results shared will highlight Merck’s unwavering commitment to advancing innovative research in hypercholesterolemia and in the syndrome of combined post- and precapillary...

BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adolescents with moderate-to-severe atopic dermatitis aged 6 months to <18 years. Lebrikizumab met both co-primary and key secondary endpoints, delivering near-complete skin clearance, reduced disease severity, itch relief...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “Alto enters 2026 with a very strong clinical and financial foundation,” said Amit Etkin, M.D., Ph.D., founder and...